Lonza Group AG (LZAGY)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Lonza Group AG (LZAGY) with AI Score 44/100 (Weak). Lonza Group AG is a global contract development and manufacturing organization (CDMO) serving the pharmaceutical, biotech, and nutrition markets. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 18, 2026Lonza Group AG (LZAGY) Healthcare & Pipeline Overview
Lonza Group AG is a leading global CDMO providing integrated solutions across the pharmaceutical, biotech, and nutrition industries, distinguished by its broad service portfolio, technological innovation in cell and gene therapy, and established presence in key global markets, positioning it as a critical partner for drug developers.
Investment Thesis
Lonza Group AG presents a notable research candidate driven by the increasing demand for outsourced pharmaceutical development and manufacturing services. The company's diverse service portfolio, spanning biologics, small molecules, cell and gene therapies, and capsules & health ingredients, positions it to capitalize on multiple growth avenues within the healthcare sector. Lonza's established presence in key global markets and its focus on innovation, particularly in cell and gene therapy, provide a competitive edge. With a P/E ratio of 37.70 and a profit margin of 13.9%, the company demonstrates financial stability. Upcoming catalysts include continued expansion in the cell and gene therapy market and strategic partnerships to enhance its service offerings. Potential risks include increased competition in the CDMO space and regulatory challenges associated with novel therapies.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $43.99 billion reflects Lonza's significant presence in the healthcare sector.
- P/E ratio of 37.70 indicates investor confidence in the company's earnings potential.
- Profit margin of 13.9% demonstrates Lonza's ability to generate profits from its operations.
- Gross margin of 34.6% highlights the efficiency of Lonza's manufacturing processes and pricing strategies.
- Dividend yield of 0.82% provides a steady income stream for investors.
Competitors & Peers
Strengths
- Diverse service portfolio across biologics, small molecules, and cell and gene therapies.
- Global presence and established relationships with key customers.
- Strong reputation for quality and reliability.
- Focus on innovation and advanced technologies.
Weaknesses
- High capital expenditures required for manufacturing infrastructure.
- Exposure to regulatory risks and compliance requirements.
- Dependence on key customers and contracts.
- Potential for supply chain disruptions.
Catalysts
- Ongoing: Continued expansion in the cell and gene therapy market, driven by increasing demand for personalized medicine.
- Ongoing: Strategic partnerships and collaborations to enhance service offerings and expand market reach.
- Upcoming: Potential regulatory approvals for novel therapies and drug products manufactured by Lonza.
- Ongoing: Increased outsourcing of pharmaceutical manufacturing by pharmaceutical and biotech companies.
Risks
- Potential: Increased competition in the CDMO space, leading to pricing pressures and reduced market share.
- Potential: Regulatory challenges and compliance requirements associated with novel therapies and drug products.
- Potential: Economic downturns that could reduce demand for pharmaceutical products and services.
- Ongoing: Currency risk associated with fluctuations in the exchange rate between the U.S. dollar and the Swiss franc.
- Ongoing: Risks associated with operating in multiple countries, including political instability and regulatory changes.
Growth Opportunities
- Expansion in Cell and Gene Therapy: The cell and gene therapy market is experiencing rapid growth, driven by breakthroughs in personalized medicine and the potential to treat previously incurable diseases. Lonza's Cell & Gene segment is well-positioned to capitalize on this trend, offering contract development and manufacturing services for a range of cell therapies, gene therapies, and exosome-based therapies. The global cell and gene therapy market is projected to reach $55.76 billion by 2027, growing at a CAGR of 33.9% from 2020. Lonza's investment in advanced technologies and platforms for cell and gene therapy manufacturing provides a competitive advantage in this high-growth market.
- Strategic Partnerships and Collaborations: Lonza can drive growth by forming strategic partnerships and collaborations with pharmaceutical and biotech companies. These partnerships can provide access to new technologies, expand its service offerings, and secure long-term contracts. For example, collaborating with a company specializing in drug delivery technologies could enhance Lonza's capabilities in developing and manufacturing complex drug products. These collaborations would enable Lonza to offer more comprehensive solutions to its customers and strengthen its position as a preferred CDMO partner. The timeline for realizing the benefits of these partnerships would depend on the specific agreements and the time required to integrate new technologies and services.
- Geographic Expansion in Emerging Markets: Expanding its presence in emerging markets, such as Asia and Latin America, presents a significant growth opportunity for Lonza. These regions are experiencing increasing demand for pharmaceutical products and services, driven by growing populations, rising healthcare expenditures, and improving access to healthcare. Establishing manufacturing facilities and expanding its sales and marketing efforts in these markets would enable Lonza to tap into new customer bases and diversify its revenue streams. The timeline for geographic expansion would depend on regulatory approvals, infrastructure development, and market entry strategies.
- Increased Outsourcing of Pharmaceutical Manufacturing: The trend of pharmaceutical companies outsourcing their manufacturing activities is expected to continue, driven by the desire to reduce costs, improve efficiency, and focus on core competencies. Lonza is well-positioned to benefit from this trend, offering a comprehensive range of manufacturing services for both biologics and small molecules. By providing high-quality manufacturing services at competitive prices, Lonza can attract new customers and expand its market share. The timeline for realizing the benefits of increased outsourcing would depend on the overall growth of the pharmaceutical industry and the adoption of outsourcing strategies by pharmaceutical companies.
- Development of Innovative Dosage Form Solutions: Lonza's Capsules & Health Ingredients segment can drive growth by developing innovative dosage form solutions that improve drug delivery and patient compliance. This includes developing capsules with enhanced bioavailability, controlled-release properties, and targeted delivery mechanisms. By offering these innovative solutions, Lonza can differentiate itself from competitors and attract customers seeking advanced drug delivery technologies. The global drug delivery market is projected to reach $243.7 billion by 2027, growing at a CAGR of 7.8% from 2020. Lonza's focus on innovation in dosage form solutions positions it to capitalize on this growing market.
Opportunities
- Expansion in emerging markets.
- Increased outsourcing of pharmaceutical manufacturing.
- Development of innovative dosage form solutions.
- Strategic partnerships and collaborations.
Threats
- Increased competition in the CDMO space.
- Pricing pressures from pharmaceutical companies.
- Technological advancements that could disrupt the industry.
- Economic downturns that could reduce demand for pharmaceutical products.
Competitive Advantages
- Extensive manufacturing capabilities and infrastructure.
- Strong reputation for quality and reliability.
- Deep expertise in biologics, small molecules, and cell and gene therapies.
- Long-standing relationships with key customers.
- Global presence and reach.
About LZAGY
Founded in 1897 in Switzerland, Lonza began as an energy company before transitioning into chemical production and eventually specializing in life sciences. Today, Lonza Group AG stands as a prominent contract development and manufacturing organization (CDMO), offering a comprehensive suite of services across the pharmaceutical, biotech, and nutrition sectors. The company operates through four key segments: Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients. The Biologics segment focuses on the development and manufacturing of biopharmaceuticals, supporting clinical and commercial manufacturing needs throughout the entire product lifecycle. The Small Molecules segment provides integrated services for small molecule drug substances, from design and development to manufacturing. The Cell & Gene segment is dedicated to advancing technologies and platforms for cell and gene therapies, offering contract development, manufacturing services, and regulatory support. The Capsules & Health Ingredients segment provides capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. With a global presence spanning Europe, North America, Latin America, Asia, and Australia, Lonza serves a diverse clientele, ranging from emerging biotech firms to established pharmaceutical giants. Its commitment to innovation and quality has solidified its position as a trusted partner in the healthcare industry.
What They Do
- Contract development and manufacturing of biopharmaceuticals.
- Integrated development and manufacturing services for small molecule drug substances.
- Development of technologies and platforms for cell and gene therapies.
- Contract development and manufacturing services for cell and gene therapies.
- Regulatory support for cell and gene therapies.
- Supply of specialty raw materials and enabling technology solutions.
- Offer capsules, dosage form solutions, and health ingredients.
- Serve pharmaceutical and nutraceutical customers.
Business Model
- Fee-for-service model for contract development and manufacturing services.
- Sales of capsules, dosage form solutions, and health ingredients.
- Licensing of technologies and platforms.
- Strategic partnerships and collaborations.
Industry Context
Lonza operates within the rapidly growing contract development and manufacturing organization (CDMO) industry. The increasing complexity of drug development, coupled with the rising demand for specialized manufacturing capabilities, is driving growth in this sector. The global CDMO market is projected to reach $225.27 billion by 2028, growing at a CAGR of 8.5% from 2021. Lonza competes with other major CDMOs, such as ARGNF (argenx SE), CHALF (Charles River Laboratories International, Inc.), and DSNKY (Daiichi Sankyo Company, Limited). Lonza's broad service portfolio and focus on innovation position it as a key player in this competitive landscape.
Key Customers
- Pharmaceutical companies.
- Biotech companies.
- Nutraceutical companies.
- Research institutions.
Financials
Chart & Info
Lonza Group AG (LZAGY) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
-
Stocks That Hit 52-Week Highs On Wednesday
· Feb 12, 2020
-
Stocks That Hit 52-Week Highs On Tuesday
· Feb 11, 2020
-
Stocks That Hit 52-Week Highs On Wednesday
· Jan 22, 2020
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LZAGY.
Price Targets
Wall Street price target analysis for LZAGY.
MoonshotScore
What does this score mean?
The MoonshotScore rates LZAGY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Wolfgang Wienand
Chief Executive Officer
Wolfgang Wienand is the Chief Executive Officer of Lonza. His career spans various leadership roles within the pharmaceutical and chemical industries. Prior to joining Lonza, he held executive positions at Siegfried Holding AG and Evonik Industries. He brings extensive experience in strategic management, operational excellence, and business development. His educational background includes advanced degrees in chemistry and business administration, providing a strong foundation for leading a complex organization like Lonza.
Track Record: Since assuming the role of CEO, Wolfgang Wienand has focused on driving growth through strategic investments in key areas such as cell and gene therapy. He has overseen the expansion of Lonza's manufacturing capabilities and the strengthening of its customer relationships. Under his leadership, Lonza has continued to innovate and adapt to the evolving needs of the pharmaceutical and biotech industries.
Lonza Group AG ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that trades on U.S. stock exchanges. LZAGY is a Level 1 ADR, meaning it trades over-the-counter (OTC) and has less stringent regulatory requirements than listed ADRs. It allows U.S. investors to invest in Lonza Group AG without directly dealing with foreign exchanges.
- Home Market Ticker: SIX Swiss Exchange, Switzerland
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: LZAG
LZAGY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited financial disclosure and may not meet the listing requirements of major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the potential for limited information and liquidity compared to exchange-listed stocks. This tier is distinct from higher OTC tiers like OTCQX and OTCQB, which have more stringent listing standards and reporting requirements.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Lower trading volumes and liquidity.
- Wider bid-ask spreads.
- Potential for price volatility.
- Higher risk of fraud or manipulation.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review the company's risk factors and potential liabilities.
- Check for any legal or regulatory issues.
- Consult with a financial advisor.
- Understand the risks associated with OTC investing.
- Lonza Group AG is a well-established company with a long operating history.
- The company has a significant market capitalization.
- Lonza Group AG is a global company with operations in multiple countries.
- The company has a diverse service portfolio and a strong reputation in the healthcare industry.
What Investors Ask About Lonza Group AG (LZAGY)
What does Lonza Group AG do?
Lonza Group AG is a leading global contract development and manufacturing organization (CDMO) that provides a comprehensive range of services to the pharmaceutical, biotech, and nutrition industries. The company operates through four segments: Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients. Lonza offers services such as drug substance and drug product manufacturing, cell and gene therapy development, and capsule and dosage form solutions. Its services support customers across various aspects of design, development, and manufacturing.
What do analysts say about LZAGY stock?
Analyst consensus on LZAGY stock is currently pending. Key valuation metrics to consider include the company's P/E ratio of 37.70, profit margin of 13.9%, and gross margin of 34.6%. Growth considerations include the company's expansion in the cell and gene therapy market, strategic partnerships, and geographic expansion in emerging markets. Investors should conduct their own research and consult with a financial advisor before making any investment decisions.
What are the main risks for LZAGY?
The main risks for Lonza Group AG include increased competition in the CDMO space, regulatory challenges associated with novel therapies, economic downturns that could reduce demand for pharmaceutical products, currency risk associated with fluctuations in exchange rates, and risks associated with operating in multiple countries. Additionally, the company faces risks related to supply chain disruptions and dependence on key customers and contracts. Investors should carefully consider these risks before investing in LZAGY.
How does Lonza Group AG navigate regulatory approval processes?
Lonza Group AG navigates regulatory approval processes by maintaining a strong focus on compliance and quality. The company has extensive experience working with regulatory agencies such as the FDA and EMA, and it has a proven track record of successfully obtaining approvals for its customers' products. Lonza invests in robust quality control systems and processes to ensure that its manufacturing facilities meet the highest standards. The company also provides regulatory support to its customers, helping them navigate the complex regulatory landscape and prepare for inspections.
How does Lonza Group AG manage patent expiration risks?
As a CDMO, Lonza Group AG is less directly exposed to patent expiration risks compared to pharmaceutical companies that develop and market their own drugs. However, Lonza's business can be indirectly affected by patent expirations if its customers experience a decline in sales due to generic competition. To mitigate this risk, Lonza focuses on diversifying its service offerings and expanding into new therapeutic areas. The company also invests in innovative technologies and platforms to stay ahead of the curve and provide value-added services to its customers.
What are the key factors to evaluate for LZAGY?
Lonza Group AG (LZAGY) currently holds an AI score of 44/100, indicating low score. Key strength: Diverse service portfolio across biologics, small molecules, and cell and gene therapies.. Primary risk to monitor: Potential: Increased competition in the CDMO space, leading to pricing pressures and reduced market share.. This is not financial advice.
How frequently does LZAGY data refresh on this page?
LZAGY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven LZAGY's recent stock price performance?
Recent price movement in Lonza Group AG (LZAGY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diverse service portfolio across biologics, small molecules, and cell and gene therapies.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for LZAGY, which may provide additional insights.
- OTC market data may have limited availability and reliability.